(1 - 22 from 28
)
AstraZeneca pill slows thyroid cancer progression - Reuters
www.reuters.com
Peter Langmuir, executive director of medical science, told Reuters that AstraZeneca would use the data to file for regulatory approval in MTC ...
www.pharmatimes.com › news › astrazeneca_thyroid_cancer_drug_impr...AstraZeneca thyroid cancer drug impresses in Phase III ...
www.pharmatimes.com
Peter Langmuir, executive director of medical science at the Anglo-Swedish drugmaker, said that patients with advanced MTC “currently have ...
AZ Completes ZEST Enrollment - Contract Pharmawww.contractpharma.com › contents › view_breaking-news › az-complete...
www.contractpharma.com
30 Nov · Peter Langmuir, Medical Science Director at AstraZeneca. ZEST is part of a Phase III clinical trial program to gain a broad understanding of how ...
AstraZeneca Says Thyroid Cancer Drug Vandetanib Meets Primary...
www.rttnews.com
AstraZeneca Says Thyroid Cancer Drug Vandetanib Meets Primary ... Peter Langmuir, M.D. Executive Director, Medical-Science, AstraZeneca said, "Patients with advanced medullary ...
sorted by relevance / date